Table 3.

Oncologic outcomes by study group

Outcome	No. (%) of patients;* residence		p value
	Urban and suburban n = 219	Rural and remote n = 55
Tumour size,† cm, median (IQR)	4.0 (2.5–6.5)	5.0 (2.7–8.2)	0.07
Location of tumour			0.74
Antrum	47 (21)	8 (15)
Body	32 (15)	8 (15)
Cardia	8 (4)	2 (4)
Pylorus	1 (0.5)	0 (0)
Lauren classification			0.14
Intestinal	44 (20)	7 (13)
Diffuse	26 (12)	9 (16)
Mixed	9 (4)	0 (0)
Pathologic stage			0.31
0	2 (1)	0 (0)
I	51 (23)	11 (20)
II	25 (11)	9 (16)
III	61 (28)	13 (24)
IV	34 (16)	14 (25)
Grade			0.97
I	14 (6)	3 (5)
II	59 (27)	14 (25)
III	128 (58)	32 (58)
pT stage			0.014
T0	4 (2)	0 (0)
T1	34 (16)	9 (16)
T2	27 (12)	3 (5)
T3	42 (19)	22 (40)
T4	66 (30)	12 (22)
pN stage			0.36
N0	57 (26)	15 (27)
N1	26 (12)	5 (9)
N2	34 (16)	6 (11)
N3	55 (25)	21 (38)
Total no. of lymph nodes resected, median (IQR)	28 (21–39)	28 (21–43)	0.64
No. of positive lymph nodes, median (IQR)	2 (0–9)	5 (0–16)	0.23
LV invasion	79 (36)	21 (38)	0.27
PN invasion	65 (30)	22 (40)	0.34
pM stage			0.67
M0	142 (65)	37 (67)
M1	31 (14)	10 (18)
Site of metastasis			0.12
Peritoneum	23 (11)	7 (13)
Liver	2 (1)	0 (0)
Nonregional lymph nodes	6 (3)	1 (2)
Bone	0 (0)	1 (2)
Invasion into surrounding structure	0 (0)	1 (2)
pCR	4 (3)	0 (0)	0.58
Follow-up time, mo, median (IQR)	18 (6–37)	11 (6–39)	0.40

IQR = interquartile range; LV = lymphovascular; M = distant metastasis; N = lymph node metastasis; p = pathologic or post-treatment; pCR = pathologic complete response; PN = perineural; T = tumour extension.

^*Unless indicated otherwise.

^†Greatest dimension of tumour as measured by pathologist.